title: [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
abstract: The efficacy of various combination chemotherapies employed for the 37 patients with low-grade non-Hodgkin's lymphoma between 1981 and 1994 was evaluated retrospectively. The overall survival at 5 years was 68%. The 5-year survival of the 27 patients achieving complete response (CR) was 87%, which was significantly higher than that of 9 patients with partial response (p = 0.0005). The CR rate of stage III and IV patients was 64% for the 22 patients treated with ACOMP-B (D), and was 38% for 8 others treated with milder chemotherapy regimens including VEPA. The 22 advanced stage patients had a 5-year survival of 88% after the treatment with ACOMP-B (D) and 69% of them remained free of disease at 5 years. In this group no relapse occurred beyond 1.6 years after treatment. These findings suggest a possible role of third generation chemotherapy in the treatment of patients with advanced-stage low-grade non-Hodgkin's lymphoma.
authors.affiliation: Department of Internal Medicine, Yokohama Ekisaikai Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Hattori
authors.forename: S
authors.initials: S
authors.lastname: Motomura
authors.forename: N
authors.initials: N
authors.lastname: Tomita
authors.forename: J
authors.initials: J
authors.lastname: Taguchi
authors.forename: J
authors.initials: J
authors.lastname: Tanabe
authors.forename: R
authors.initials: R
authors.lastname: Sakai
authors.forename: S
authors.initials: S
authors.lastname: Fujisawa
authors.forename: H
authors.initials: H
authors.lastname: Fukawa
authors.forename: H
authors.initials: H
authors.lastname: Kanamori
authors.forename: H
authors.initials: H
authors.lastname: Mouri
authors.forename: A
authors.initials: A
authors.lastname: Maruta
authors.forename: F
authors.initials: F
authors.lastname: Kodama
authors.forename: T
authors.initials: T
authors.lastname: Okubo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate